RICOVR Healthcare Effectively Tests Its Portable Device For Recognition Of THC In Human Saliva

RICOVR Healthcare's Portable Device Detects THC Effectively

September 27, 2022 : RICOVR Healthcare, the developer of XALIVA THC rapid drug test for on-site recent use detection of marijuana, documented successful testing of its P-FAB technology for detection of THC in human saliva. The current testing of subjects under the effect of marijuana started in Q1 of 2022.

In the present study, RICOVR actively collects samples before use to specify a baseline and then tests the subject’s post-marijuana assistance at sequential time increments. The testing is nearing fulfillment, and results have shown accurate THC detection at each time increment. “Our testing indicates that our compassionate P-FAB technology will deliver a solution for employers and law enforcement to detect current marijuana use at workplaces and roadside. This will assist improve safety by providing the tool to make better-informed and more rightful decisions around THC impairment amid legalization,” said Dr. Himanshu Bhatia, founder, and CEO of RICOVR Healthcare.

Conventional urine and hair-based test methods detect THC metabolites, suggesting one-time use for 30 days or more. California’s new off-duty usage employee protection law bans the use of urine and hair cannabis testing for this cause. With the legalization of recreational marijuana in 19 states and an additional 37 with legal, medical marijuana, there is a strong need for a test that only notices recent use that better aligns with impairment to uphold workplace safety.

The company’s technology employs a novel plasmonic fiber-optic absorbance biosensor (P-FAB) that only catches recent use (within 8 to 10 hours) and provides justice to legal users outside work while ensuring security on the job. With high accuracy, the XALIVA platform furnishes real-time THC detection employing saliva within five minutes. The device is a portable and cost-effective answer to screen employees at the workplace. RICOVR will develop the results of this study with more user samples and is also in talks with leading academic institutions for partnership.